Recce Pharmaceuticals Ltd
ASX:RCE
Recce Pharmaceuticals Ltd
ASX:RCE
Price:
0.445
AUD
22.76%
Market Cap:
128.3m
AUD
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
-7.6
Current
-10.8
Median
13.3
Industry
Higher
than median
Lower
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=-7.6
Enterprise Value
/
126.4m AUD
EBITDA
-16.6m AUD
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
-8.9
2-Years Forward
EV/EBITDA
-3.5
3-Years Forward
EV/EBITDA
-10.7
You don't have any saved screeners yet
